Cargando…

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

Latent reservoir persistence remains a major obstacle for curing human immunodeficiency virus type 1 (HIV-1) infection. Thus, strategies for the elimination of latent HIV-1 are urgently needed. As a bromodomain and extra-terminal (BET) inhibitor, BMS-986158 has been used in clinical trials for advan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xu-Sheng, Tian, Ren-Rong, Ma, Meng-Di, Luo, Rong-Hua, Yang, Liu-Meng, Peng, Guang-Hui, Zhang, Mi, Dong, Xing-Qi, Zheng, Yong-Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952190/ https://www.ncbi.nlm.nih.gov/pubmed/35337136 http://dx.doi.org/10.3390/ph15030338

Ejemplares similares

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
por: Hilton, John, et al.
Publicado: (2022)

Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
por: Sun, Hui-Yan, et al.
Publicado: (2022)

Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis
por: Fu, Rong, et al.
Publicado: (2022)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
por: Wu, Dayu, et al.
Publicado: (2022)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
por: Shi, Xiyao, et al.
Publicado: (2022)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
por: Trivedi, Archit, et al.
Publicado: (2020)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer
por: Chetry, Mandika, et al.
Publicado: (2022)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins
por: Chabert, Clovis, et al.
Publicado: (2017)

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease
por: Manni, Michelle L., et al.
Publicado: (2017)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors
por: Chen, Siao, et al.
Publicado: (2021)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
por: Martella, Noemi, et al.
Publicado: (2023)

Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins
por: Ajgaonkar, Sandeep, et al.
Publicado: (2023)

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
por: Wadhwa, Elizabeth, et al.
Publicado: (2016)

Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
por: Meng, Yuting, et al.
Publicado: (2021)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors
por: Kitazawa, Satoshi, et al.
Publicado: (2017)

Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors
por: Groves, Andrew, et al.
Publicado: (2022)

Bromodomain and extra‐terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension
por: Mumby, Sharon, et al.
Publicado: (2016)

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
por: Wong, C, et al.
Publicado: (2014)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
por: De Riick, Jan, et al.
Publicado: (2013)

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function
por: Pinz, Sophia, et al.
Publicado: (2015)

77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021)

Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation
por: Nguyen, Thi Hiep, et al.
Publicado: (2016)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit
por: Fish, Paul V., et al.
Publicado: (2012)

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
por: Mensah, Afua A., et al.
Publicado: (2018)

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins
por: Bai, Ping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_12cr62pm0t24btgupfhj6gbghf